anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The relationship between transcription and protein expression is complex. We identified polysome-associated RNA transcripts in the somata and central terminals of mouse sensory neurons in control, painful (plus nerve growth factor), and pain-free conditions (Nav1.7-null mice). The majority (98%) of translated transcripts are shared between male and female mice in both the somata and terminals. Some transcripts are highly enriched in the somata or terminals. Changes in the translatome in painful and pain-free conditions include novel and known regulators of pain pathways. Antisense knockdown of selected somatic and terminal polysome-associated transcripts that correlate with pain states diminished pain behavior. Terminal-enriched transcripts included those encoding synaptic proteins (e.g., synaptotagmin), non-coding RNAs, transcription factors (e.g., Znf431), proteins associated with transsynaptic trafficking (HoxC9), GABA-generating enzymes (Gad1 and Gad2), and neuropeptides (Penk). Thus, central terminal translation may well be a significant regulatory locus for peripheral input from sensory neurons.
Community-dwelling elderly healthy individuals. The participants were given the dysphagia screening questionnaire, consisted of 16 questions and the several sips of water to drink (clinical water drinking test for dysphagia screening).
Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
The present invention relates to a nasal cavity and oral cavity cleansing solution. More specifically, the present invention relates to a nasal cavity and oral cavity cleansing solution capable of cleansing a mucous membrane of a nasal cavity and an oral cavity. According to the present invention, a cleansing solution for cleansing a nasal cavity and/or an oral cavity contains high concentration oxygen of 80 ppm or more as an effective ingredient. The present invention can activate the functions of a mucous membrane and cilia formed on the mucous membrane by cleansing a nasal cavity and an oral cavity with a mucous membrane cleansing solution consisting of high concentration oxygen water to supply oxygen directly to the mucous membrane. In addition, since the mucous membrane cleansing solution, according to the present invention, is made of the same ingredient as water, in spite of being used repeatedly for long hours, a side effect caused by artificial chemicals can be minimized. Moreover, the mucous membrane cleansing solution can effectively alleviate symptoms such as rhinitis, a sore throat, or the like, because high concentration oxygen dissolved in water treats various inflammations or the like in the mucous membrane.
Many studies have attempted to identify the root cause of dyslexia. Different theories of dyslexia have proposed either a phonological, attentional, or visual deficit. While research has used eye-tracking to study dyslexia, only two previous studies have used the moving-window paradigm to explore the perceptual span in dyslexic reading, and none have done so in visual search. The present study analysed the perceptual span using both reading and visual search tasks to identify language-independent attentional impairments in dyslexics. We found equivocal evidence that the perceptual span was impaired in dyslexic reading and no evidence of impairment in visual search. However, dyslexic participants did show deficits in the visual search task, with lower search accuracy and shorter saccades compared with controls. These results lend support for a visual, rather than attentional or phonological, account of dyslexia.
Part 2: Pilot RCT. Will randomize 66 parents to 16 weekly 60-90 minute (approx) sessions of MCGT or SP delivered via videoconferencing. Again, sessions will be audio recorded. If the participant provides us with permission, we also audio/video record the sessions. We will examine aspects of study implementation \& therapy process, including a) recruitment progress, b) implementation of the intervention, c) administration of the assessments, \& d) retention. We will also examine acceptability, defined as measures of satisfaction at T3. Psychosocial outcomes will be assessed with self-report measures at 4 time points: pre-intervention (T1), mid-intervention (T2), post-intervention (T3), \& at 3-months post-intervention (T4). Post-intervention qualitative exit interviews will assess acceptability of the intervention. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention .
Approximately 1500 students in the 3rd grade (100 students per school) will complete pre-tests, post-tests, and 12- and 24-month follow-ups. Students whose school is randomized to the control condition (12 schools) will not receive the LifeSkills Training intervention, but will receive the health education content normally provided by their schools.
PURPOSE: To obtain a liquid or gel-like cloudy bathing agent containing an inorganic pigment, a dispersant, and a xanthane gum in a specific ratio, and preventing the sedimentation of the inorganic pigment. CONSTITUTION: >=0.3% of a xanthane gum is added to the mixture of an inorganic pigment with a dispersant or to the inorganic pigment coated with the clispersant. The inorganic pigment (e.g. titanium dioxide) is added in an amount of 0.1-30%, and the dispersant used for dispersing the inorganic pigment is added in a concentration having a ratio of 1:50 to 50:1 to the inorganic pigment. The dispersant includes a water-soluble polymer (e.g. sodium polyacrylate), and 10-90% of a polyhydric alcohol is preferably further added to prevent the deterioration in the dispersibility of the inorganic pigment. The bathing agent does not produce foam, does not float an oil, has a homogeneous and stable cloudy property, further enhances the psychological effect of the bathing by the cloudiness of the inorganic pigment, and enhances the bath-warmth effect.
PURPOSE: To provide a novel pharmaceutical compsn. in a form of nanocapsule colloid suspension liquid containing a surfactant dissolved in the liquid and plural nanocapsules having <500 nm diameter comprising an oil layer of the oil suspended in the liquid. CONSTITUTION: The nanocapsule is essentially produced by capsuling a water phase comprising an active material as a therapeutic medicine in water and a soln. or suspension (pH between 1 to 7) of a surfactant. The wall of the nanocapsule consists of poly(alkyl 2-cyanoacrylate), wherein alkylradicals have 1 to 6 carbon atoms. The pharmaceutical compsn. is especially suitable for oral medication of polypeptide and polysaccharide.
The efficacy of TEMODAR was evaluated in MK-7365-051 (NCT00006353), a randomized (1:1), multicenter, open-label trial. Eligible patients were required to have newly diagnosed glioblastoma. Patients were randomized to receive either radiation therapy alone or concomitant TEMODAR 75 mg/m2 once daily starting the first day of radiation therapy and continuing until the last day of radiation therapy for 42 days (with a maximum of 49 days), followed by TEMODAR 150 mg/m2 or 200 mg/m2 once daily on Days 1 to 5 of each 28-day cycle, starting 4 weeks after the end of radiation therapy and continuing for 6 cycles. In both arms, focal radiation therapy was delivered as 60 Gy/30 fractions and included radiation to the tumor bed or resection site with a 2- to 3-cm margin. PCP prophylaxis was required during the concomitant phase regardless of lymphocyte count and continued until recovery of lymphocyte count to Grade 1 or less. The major efficacy outcome measure was overall survival.

A total of 573 patients were randomized, 287 to TEMODAR and radiation therapy and 286 to radiation therapy alone. At the time of disease progression, TEMODAR was administered as salvage therapy in 161 patients of the 282 (57%) in the radiation therapy alone arm and 62 patients of the 277 (22%) in the TEMODAR and radiation therapy arm.

The addition of concomitant and maintenance TEMODAR to radiation therapy for the treatment of patients with newly diagnosed glioblastoma showed a statistically significant improvement in overall survival compared to radiotherapy alone (Figure 1). The hazard ratio (HR) for overall survival was 0.63 (95% CI: 0.52, 0.75) with a log-rank P<0.0001 in favor of the TEMODAR arm. The median overall survival was 14.6 months in the TEMODAR arm and 12.1 months for radiation therapy alone arm.
MESNEX may be given on a fractionated dosing schedule of a single bolus injection followed by two oral administrations of MESNEX tablets as outlined below. 

MESNEX injection is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage (w/w) at the time of ifosfamide administration. MESNEX tablets are given orally in a dosage equal to 40% of the ifosfamide dose 2 and 6 hours after each dose of ifosfamide. The total daily dose of MESNEX is 100% of the ifosfamide dose. The recommended dosing schedule is outlined in Table 2.

The efficacy and safety of this ratio of intravenous and oral MESNEX has not been established as being effective for daily doses of ifosfamide higher than 2 g/m2. 

Patients who vomit within two hours of taking oral MESNEX should repeat the dose or receive intravenous MESNEX.
Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered.  The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.
Wheezing is a high pitched, whistling sound generated when air flows through narrowed airways and is often equated with asthma. However, wheezing may be a presenting symptom of various other conditions including structural lesions of the airways, foreign body aspiration, pulmonary infections as well as cardiac causes. Underlying etiology of wheezing may also vary with age. Detailed history, physical examination, and laboratory investigations are often required to identify the underlying etiology of wheezing. Additional studies may sometimes be needed to accurately identify the underlying etiology such as pulmonary function test or spirometry, chest radiography (chest X-ray), and bronchoscopy. This review article discusses the common causes of wheezing encountered in clinical practice. [Pediatr Ann. 2024;53(5):e189-e194.].
The Isometric Exercise Program which comprises targeted exercises for declining pain, improving function and performance, exercises were focused only on shoulder flexion, extension, abduction, adduction, internal rotation and external rotation. Exercises were performed via Thera Bands, free weights and resistance. Each repetition was of 10 to 15 seconds and 10 to 15 number of repetition total of three sets according to FITT formula. Under the supervision of a therapist, these exercises were performed three times each week. Every training session lasts 35 to 40 minutes, with a 5-minute warm-up and a 5-minute cool-down in between. Instruction in the correct form and technique was provided to participants throughout the intervention, and their development was closely evaluated to guarantee safety and effectiveness. Total duration of 35 to 40-minute session three sessions per week total four weeks of intervention, reading will be taken on baseline and after 2nd week and 4th week.
Inhibition of megacytosis in cancer cells has been shown to enhance the anticancer efficacy of photodynamic therapy (PDT). A method for treating cancer in a subject in need thereof comprises administering to a subject having cancer an effective amount of a combination of one or more inhibitors of megacell potion and PDT. Also provided are pharmaceutical compositions comprising a combination of an inhibitor of megaloblastic actions and a photosensitizer. The method is particularly effective for treating PDT resistant cancers. An exemplary inhibitor of megalin is 5- (N-ethyl-N-isopropyl) amiloride (EIPA). An exemplary photosensitizer is chlorin 6 (Ce 6).
BACKGROUND: The aim of this double-blind, placebo-controlled study was to investigate the effect of vitamin E supplementation as an addition to a commercial renal diet on survival time of cats with different stages of chronic kidney disease (CKD). In addition, we were interested whether vitamin E supplementation affects selected oxidative stress and clinical parameters. Thirty-four cats with CKD and 38 healthy cats were included in the study. Cats with CKD were classified according to the IRIS Guidelines; seven in IRIS stage 1, 15 in IRIS stage 2, five in IRIS stage 3 and seven in IRIS stage 4. Cats with CKD were treated according to IRIS Guidelines. Cats with CKD were randomly assigned to receive vitamin E (100 IU/cat/day) or placebo (mineral oil) for 24 weeks in addition to standard therapy. Plasma malondialdehyde (MDA) and protein carbonyl (PC) concentrations, DNA damage of peripheral lymphocytes and plasma vitamin E concentrations were measured at baseline and four, eight, 16 and 24 weeks thereafter. Routine laboratory analyses and assessment of clinical signs were performed at each visit.
RESULTS: Vitamin E supplementation had no effect on the survival time and did not reduce the severity of clinical signs. Before vitamin E supplementation, no significant differences in vitamin E, MDA and PC concentrations were found between healthy and CKD cats. However, plasma MDA concentration was statistically significantly higher (p = 0.043) in cats with early CKD (IRIS stages 1 and 2) than in cats with advanced CKD (IRIS stages 3 and 4). Additionally, DNA damage was statistically significantly higher in healthy cats (p ≤ 0.001) than in CKD cats. Plasma vitamin E concentrations increased statistically significantly in the vitamin E group compared to the placebo group four (p = 0.013) and eight (p = 0.017) weeks after the start of vitamin E supplementation. During the study and after 24 weeks of vitamin E supplementation, plasma MDA and PC concentrations and DNA damage remained similar to pre-supplementation levels in both the placebo and vitamin E groups.
CONCLUSIONS: Vitamin E supplementation as an addition to standard therapy does not prolong survival in feline CKD.
The purpose of this study is to determine the duration and time course of the thermic effect of single meals consumed by subjects who have been previously fasting for 12 hours overnight. Capturing the full thermic effect of a meal may take up to 8 hours, depending on the calorie load, nutrient composition of the meal, and rate of digestion. The investigators will test meals consisting of conventional foods that are low (20% of energy), moderate (40% of energy) or high (60% of energy) in fat calories, as fat is thought to slow the digestive process. The investigators will test a liquid meal, that is high (60% of energy) in fat calories, as liquid foods are thought to move more quickly through the digestive process. Another purpose of this study is to determine the test-retest reproducibility for the meals described above. To accomplish reproducibility, a volunteer will be permitted to repeat a test day two times using the same test meal.
A medical diagnostic kit (MDK) includes a universal cable storage compartment (UCSC), a deck, and switchable multi-port hubs (SMPHs). Configurable cable compartments in the UCSC accommodate cables of clinical examination devices (CEDs) without mutual entanglement. The deck positioned on the UCSC supports the CEDs and includes cutouts into the UCSC for cable management. The SMPHs permanently connect CED cable connectors and selectively power and communicate data with the CED(s). An internal energy storage device (ESD) receives power from a multi-port charger (MPC) during charging, and delivers the power to the SMPHs for powering and communicating data with the CED(s) when the casing is opened. An activated, hubs disconnection switch interrupts power delivery from the ESD to the SMPHs when the casing is closed. The MDK includes a diagnostic computer with a software application for activating the CED(s), executing media conference connections, managing medical data, and facilitating remote real-time medical examinations.
To assess the effectiveness and safety of combining Saccharomyces boulardii powder with triple therapy as a primary approach for eradicating H. pylori infection, a total of 144 patients who tested positive for H. pylori and diagnosed with non-ulcer dyspepsia underwent endoscopy at two national centers between June 2017 and March 2019 were included. The patients were categorized into three groups using a subsection randomization method and received initial H. pylori eradication treatments. Microbial composition, eradication rates, symptom alleviation, and adverse reactions were monitored on the 14th and 44th days post-treatment. According to PP analysis showed the eradication rates for the SRAC group was 75%, BRAC was 93.18% and RAC was 65.2%. Group BRAC exhibited a marginally higher eradication rate compared to other groups. However, patients receiving Saccharomyces boulardii treatment exhibited an overall reduction in initial dyspepsia symptoms by the end of the treatment period. When employed as a primary strategy, the combination of Saccharomyces boulardii powder with triple therapy displayed notable efficacy and smaller gastrointestinal side effects in eradicating initial H. pylori infections among non-ulcer dyspepsia patients. Moreover, this approach demonstrated advantages in alleviating symptoms, exhibited favorable tolerance, and maintained a high level of clinical safety.
PURPOSE: Management of dual antiplatelet therapy (DAPT) in patients on venoarterial-extracorporeal membrane (VA-ECMO) after acute myocardial infarction (AMI) is challenging. Our objective was to describe the frequency, management and outcomes of severe bleeding complications and determine their occurrence risk factors.
MATERIAL AND METHODS: We conducted a retrospective observational cohort study including post-AMI cardiogenic shock patients requiring VA-ECMO. Severe bleeding was defined based on the Bleeding Academic Research Consortium classification. We calculated multivariable Fine-Gray models to assess factors associated with risk of severe bleeding.
RESULTS: From January 2015 to July 2019, 176 patients received VA-ECMO after AMI and 132 patients were included. Sixty-five (49%) patients died. Severe bleeding occurred in 39% of cases. Severe thrombocytopenia (< 50 G/L) and hypofibrinogenemia (<1,5 g/L) occurred in respectively 31% and 19% of patients. DAPT was stopped in 32% of patients with a 6% rate of stent thrombosis. Anticoagulation was stopped in 39% of patients. Using a multivariate competing risk model, female sex, time on ECMO, troponin at admission and Impella® implantation were independently associated with severe bleeding.
CONCLUSIONS: Bleeding complications and coagulation disorders were frequent and severe in patients on VA-ECMO after AMI, leading of antiplatelet therapy withdrawal in one third of patients.
Aquamantys 6.0 bipolar sealer \[Salient Surgical Technologies, Portsmouth, New Hampshire\] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (\<100 degrees Celsius) than standard Bovie electrocautery.
An EACA loading dose of 100 mg/kg with a max of 4-5 grams will be given up to 1 hour prior to incision. During the case, an EACA infusion of 33 mg/kg/hr (max of 1 gram/hr) will be maintained. The use of EACA will be terminated at the end of the case.
Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
The safety and effectiveness of ZENPEP for the treatment of exocrine pancreatic insufficiency have been established in pediatric patients.

Use of ZENPEP for this indication is supported by an adequate and well-controlled trial in adult and pediatric patients 7 to 17 years of age (Study 1) along with supportive data from an open-label, single arm study in 19 pediatric patients 1 to 6 years of age (Study 2). Both study populations consisted of patients with exocrine pancreatic insufficiency due to cystic fibrosis. The safety in pediatric patients in Studies 1 and 2 were similar to that observed in adult patients [see Adverse Reactions (6.1) and Clinical Studies (14)]. 

Dosages exceeding 6,000 lipase units/kg/meal have been reported postmarketing to be associated with fibrosing colonopathy and colonic strictures in pediatric patients less than 12 years of age. If there is a history of fibrosing colonopathy, monitor patients during treatment with ZENPEP because some patients may be at risk of progressing to stricture formation. Do not exceed the recommended dosage of either 2,500 lipase units/kg/meal, 10,000 lipase units/kg/day, or 4,000 lipase units/g fat ingested/day in pediatric patients greater than 12 months of age without further investigation. [see Dosage and Administration (2.2) and Warnings and Precautions (5.1)]. 

Crushing or chewing ZENPEP capsules or mixing the capsule contents in foods having a pH greater than 4.5 can disrupt the protective enteric coating on the capsule contents and result in early release of enzymes, irritation of the oral mucosa, and/or loss of enzyme activity. Instruct the patient or caregiver of the following: consume sufficient liquids (juice, water, breast milk, or formula) to ensure complete swallowing, and visually inspect the mouth of pediatric patients less than 12 months of age to ensure that no drug is retained in the mouth and irritation of the oral mucosa has not occurred [see Dosage and Administration (2.3) and Warnings and Precautions (5.2)].
Globally, hearing loss is a prevalent health condition that often goes unattended and significantly influences the quality of life of the affected individual. The prevalence of hearing loss is expected to rise in the years to come, predominantly due to the changes in the demography, increased exposure to recreational noise, and disregarding ear conditions that can account for hearing loss but are immensely preventable. A wide range of activities can be planned and organized to promote ear and hearing care and thereby contribute to our vision to prevent the consequences of unaddressed hearing loss. However, the sustainability of these events, especially in terms of accomplishing the intended outcomes, essentially depends on the involvement of the community and the political leaders. In conclusion, the strategies to promote ear and hearing care are much more essential than health interventions do; rather, these measures have social implications. The need of the hour is to create awareness among different stakeholders to ensure that we can change the perception of the masses and that ear and hearing care becomes a global public health priority.